Intermittent androgen deprivation therapy in prostate cancer: Is everything so clear?

European Urology

Volumn 63, Issue 1, 2013, Pages 121-122

  Mottet, Nicolas ^a  

^a HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; BONE DISEASE; CANCER SURVIVAL; CASTRATION; DEPRESSION; EDITORIAL; HOT FLUSH; HUMAN; LIBIDO DISORDER; METABOLIC SYNDROME X; PENIS DISEASE; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUALITY; TREATMENT DURATION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; GOSERELIN; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 84870571940     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.004     Document Type: Editorial

References (9)

1. A.J. Salonen, K. Taari, and M. Ala-Opas Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects Eur Urol 63 2013 111 120
2. E. Ng, H.H. Woo, S. Turner, E. Leong, M. Jackson, and N. Spry The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression J Urol 187 2012 2162 2166
3. P.A. Abrahamsson Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature Eur Urol 57 2010 49 59
4. N. Mottet, J. Van Damme, S. Loulidi, C. Russel, A. Leitenberger, J.M. Wolff the TAP22 Investigators Group Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial BJU Int 110 2012 1262 1269
5. M. Hussain, C.M. Tangen, and C.S. Higano Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial J Clin Oncol 30 Suppl 2012 abstract LBA 4
6. A.J. Salonen, K. Taari, M. Ala-Opas, J. Viitanen, S. Lundstedt, T.M.J. Tammela FinnProstate Group The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer J Urol 187 2012 2074 2081
7. J.M. Crook, C.J. O'Callaghan, and K. Ding A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013) [abstract 4514] J Clin Oncol 29 Suppl 7 2011
8. M. Hussain, C.M. Tangen, and C. Higano Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group trial 9346 (INT-0162) J Clin Oncol 24 2006 3984 3990
9. G.L. Shaw, P. Wilson, and J. Cuzick International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients BJU Int 99 2007 1056 1065